Morepen Laboratories net profit up to Rs 168 million in Q2

Mumbai: Morepen Laboratories has posted a net profit of Rs 167.5 million for the quarter ended 30 September 2002 as compared to Rs 133.1 million for the quarter ended 30 September 2001.

The total income has increased from Rs 1,193.7 million for quarter ended 30 September 2001 to Rs 1,493.5 million for quarter ended 30 September 2002.

Says Morepen Laboratories chairman and managing director Sushil Suri: “We recently went for a series of acquisitions to consolidate our position in the market. The acquisitions include Lemolate, a premium brand of Yash Pharma Laboratories, in the cough-and-cold category, and Burnol and Lifespring. The acquisitions have been made under the Dr Morepen umbrella.